"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors

被引：9
作者：
Mastorino, Luca [1 ,2 ]
Susca, Sara [1 ]
Cariti, Caterina [1 ]
Verrone, Anna [1 ]
Stroppiana, Elena [1 ]
Ortoncelli, Michela [1 ]
Dapavo, Paolo [1 ]
Ribero, Simone [1 ]
Quaglino, Pietro [1 ]
机构：
[1] Univ Turin, Dept Med Sci, Sect Dermatol, Turin, Italy
[2] Univ Turin, Dept Med Sci, Sect Dermatol, Via Cherasco 23, I-10126 Turin, Italy
来源：
EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷 / 12期
关键词：
biologics; IL17; inhibitors; Il23; PASI; psoriasis; superresponders;
D O I：
10.1111/exd.14731
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：2187 / 2188
页数：2
相关论文
共 9 条
  • [1] Ixekizumab for the treatment of psoriasis: up-to-date
    Craig, Sarah
    Warren, Richard B.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 549 - 557
  • [2] IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
    Eyerich, Kilian
    Weisenseel, Peter
    Pinter, Andreas
    Schaekel, Knut
    Asadullah, Khusru
    Wegner, Sven
    Munoz-Elias, Ernesto J.
    Bartz, Holger
    Taut, Friedmann J. H.
    Reich, Kristian
    [J]. BMJ OPEN, 2021, 11 (09):
  • [3] Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
    Feldman, Steven R.
    Merola, Joseph F.
    Pariser, David M.
    Zhang, Jingchuan
    Zhao, Yang
    Mendelsohn, Alan M.
    Gottlieb, Alice B.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1670 - 1675
  • [4] Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study
    Loft, N.
    Egeberg, A.
    Rasmussen, M. K.
    Bryld, L. E.
    Nissen, C., V
    Dam, T. N.
    Ajgeiy, K. K.
    Iversen, L.
    Skov, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1284 - 1291
  • [5] Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population
    Mastorino, Luca
    Roccuzzo, Gabriele
    Dapavo, Paolo
    Siliquini, Niccolo
    Avallone, Gianluca
    Rubatto, Marco
    Merli, Martina
    Agostini, Andrea
    Ribero, Simone
    Quaglino, Pietro
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (02) : 263 - 265
  • [6] Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
    Ruiz-Villaverde, Ricardo
    Vasquez-Chinchay, Fiorella
    Rodriguez-Fernandez-Freire, Lourdes
    Armario-Hita, Jose C.
    Perez-Gil, Amalia
    Galan-Gutierrez, Manuel
    [J]. LIFE-BASEL, 2022, 12 (09):
  • [7] High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab
    Talamonti, M.
    D'Adamio, S.
    Galluccio, T.
    Andreani, M.
    Pastorino, R.
    Egan, C. G.
    Bianchi, L.
    Galluzzo, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (10) : E364 - E367
  • [8] Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study
    Torres, Tiago
    Balato, Anna
    Conrad, Curdin
    Conti, Andrea
    Dapavo, Paolo
    Ferreira, Paulo
    Gaiani, Francesca
    Leite, Luiz
    Malagoli, Piergiorgio
    Mendes-Bastos, Pedro
    Megna, Matteo
    Messina, Francesco
    Nidegger, Alessia
    Odorici, Giulia
    Piaserico, Stefano
    Prignano, Francesca
    Ribero, Simone
    Ricceri, Federica
    Tonini, Annalisa
    Valerio, Joana
    Chiricozzi, Andrea
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 273 - 275
  • [9] Switching biologics in psoriasis-practical guidance and evidence to support
    Tsai, Ya-Chu
    Tsai, Tsen-Fang
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (05) : 493 - 503
1